Clinical Genomics Presents Data Supporting Novel 2-Gene Blood Test for Earlier Detection of Colorectal Cancer Recurrence at ASCO GI

Edison, NJ - Thursday, January 21, 2016

Clinical Genomics, a private company developing next-generation diagnostic tools for colorectal cancer, today announced that data supporting its 2-gene blood test for post-surgical monitoring of colorectal cancer recurrence will be presented in two posters at the 2016 American Society of Clinical Oncology 2016 Gastrointestinal Cancers Symposium (ASCO GI), taking place in San Francisco from January 21 – 23.

Studies selected to be presented at the meeting include:

  • A novel 2-gene blood test for colorectal cancer recurrence
    Presenter: Lawrence LaPointe, Ph.D.
    Abstract Number: 495
    Poster Board Number: Poster Session C Board #A8
  • Methylated BCAT1 and IKZF1 DNA in tissue and plasma from colorectal cancer cases
    Presenter: Lawrence LaPointe, Ph.D.
    Abstract Number: 543
    Poster Board Number: Poster Session C Board #C12

Data will be presented during Poster Session C, Cancers of the Colon, Rectum, and Anus, taking place on Saturday, January 23 from 7:00 AM – 7:55 AM and 12:30 PM – 2:00 PM.

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90 percent, but only about four out of 10 CRC cases are detected early. Among individuals undergoing surgical treatment for CRC, recurrence occurs in 30 to 40 percent of all cases, the majority of which present in the first two to three years following initial diagnosis and treatment.  This early and concentrated recurrence pattern is relatively unusual among cancers, and offers the opportunity for structured surveillance to detect signs of recurrence.

One element of the standard of care for post-surgical monitoring for CRC recurrence, quarterly or semi-annual blood-based testing to measure carcinoembryonic antigen (CEA) levels, has poor sensitivity and specificity. To address the need for more accurate oncology monitoring tools, Clinical Genomics has developed a new blood test to detect tumor-specific methylated DNA biomarkers that may leak from active lesions into the circulatory system. Current data suggest that a genomic test specific for these biomarkers is more sensitive than CEA testing and highly CRC tumor specific.

About Clinical Genomics
Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer diagnosis. With a broad intellectual property portfolio consisting of more than 20 patents, Clinical Genomics, via its wholly-owned subsidiary Enterix Inc., currently offers the user-friendly, patient-preferred colorectal cancer screening InSure® FIT™ assay, a fecal immunochemical test that detects blood in the stool. InSure is also marketed as a lab-based test in Australia and other countries (ColoVantage Home). Clinical Genomics has developed a sensitive and specific blood test for colorectal cancer based on methylated DNA from two genes, BCAT1 and IKZF1, and plans to offer this 2-gene test for CRC recurrence monitoring beginning later in 2016.

Clinical Genomics has offices and laboratories in Bridgewater and Edison, New Jersey and Sydney, Australia, and operates as an FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory.